TD Cowen Insights
TD Cowen Insights
TD Securities, TD Cowen
Bio-Techne at 50: CEO Kim Kelderman's Reflection on Five Decades of Platform Evolution & Strategic Priorities Ahead
13 minutes Posted Mar 20, 2026 at 7:13 pm.
0:00
13:52
Download MP3
Show notes
Recorded on 03/03/26
TD Cowen life science & diagnostic tools analyst Kyle Boucher speaks with Bio-Techne CEO Kim Kelderman at TD Cowen's 46th Annual Health Care Conference to discuss Bio-Techne's 50-year anniversary, innovation and portfolio evolution, and growth pillars ahead. Since 1976 Bio-Techne has offered a wide range of critical reagents, assays, and analytical tools for customers in diagnostic, pharma, biotech, and academic settings, and has created one of the most consumables-focused portfolios in life science tools. CEO Kelderman reflects on Bio-Techne's 50-year history, including the last 10 years where the portfolio has grown through several inorganic acquisitions addressing multiple high-growth verticals that have laid the foundation for the next leg of growth.